Halozyme Therapeutics Inc. announced that the company is commencing, through wholly owned subsidiary Atlas Merger Sub Inc., a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma Inc. for $5.60 per share in cash.

Illumina Inc. faces yet another setback from regulatory officials regarding the company’s $8 billion acquisition of GRAIL Inc. as the European Commission provided an update.

BioDelivery Sciences International Inc. entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.

Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion. 

Sanofi is investing more into its transplant operations through a $1.9 billion merger deal with Kadmon Holdings, another biopharma company that develops therapies for diseases with large unmet medical needs.

In a $7 billion transaction, San Francisco-based Datavant is merging with data network company Ciox Health to create the nation’s largest “neutral and secure health data ecosystem.”

Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital. 

ERT, a global leader in clinical endpoint data solutions, on April 28 announced the close of the company’s merger with Bioclinica, a technological and scientific leader in clinical imaging.

Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. 

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.